not tagged
not tagged
[]
which is better for cv risk in ra: triple therapy dmards or tnfi? target study
n=159 using pet/ct surrogate (endpoint responsiveness )
- either led to benefit
- both equally good
- benefit *not* linked to change in das28 a direct cv effect of ra rx? abst2215 #acr22 
Rheumatologist and clinical pharmacologist, world traveller pretences on the upswing, sometimes podcast host for @austprescriber and others. All opinions my own